The market on Monday recouped some losses as the equity benchmarks fell for the second consecutive session. The Sensex traded down 91.46 points at 27985.54, while the Nifty traded down 37.75 points at 8629.15.
Shares such as Lupin, TCS, Sun Pharma and NTPC topped the selling list on Sensex, whereas ITC, HUL and BHEL gained one to two percent.
India's largest power generation company NTPC announced profit in April-June quarter grew by 4.1 percent year-on-year to Rs. 2,369 crore from Rs. 2,276 crore in year-ago period.
Revenue stood at Rs. 19,063 crore for the quarter, up 11.5 percent YoY.
Profit was estimated at Rs. 2,346 crore on revenue of Rs. 18,487 crore for the quarter, according to average of estimates of analysts' poll.
Drug firm Lupin also announced receiving approval from the Central Drugs Standard Control Organisation (CDSCO) for Acotiamide 100 mg tablets used for treatment of indigestion.
It said the company will shortly start promoting the product in India.
In a BSE filing, it said, "Acotiamide is a first-in-class novel drug to be introduced into the Indian pharmaceutical market which could benefit millions of patients suffering from dyspepsia or indigestion, amongst the most common stomach complaints encountered in clinical practice."
Acotiamide is approved by Pharmaceuticals and Medical Devices Agency (PMDA) Japan and is actively marketed in Japan, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
